Leitlinie erklärt

• Literatur

• 1 Vilaca T, Schini M, Harnan S. et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update. Bone 2020; 137: 115457
• 2 Heidemann C, Kuhnert R, Born S et al.. 12-Monats-Prävalenz des bekannten Diabetes mellitus in Deutschland.. Journal of Health Monitoring . 2017 2.
• 3 Anagnostis P, Paschou SA, Gkekas NN. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review. Endocrine 2018; 60: 373-383
• 4 Schwartz AV, Schafer AL, Grey A et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. Journal of Bone and Mineral Research 2013; 28.6:1348–1354
• 5 Napoli N, Pannacciulli N. Vittinghoff et al. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab Res Rev 2018: 34: e2991
• 6 Langdahl BL, Silverman S, Fujiwara S et al.. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 2018; 116: 58-66
• 7 Schwartz AV, Pavo I, Alam J. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 2016; 91: 152-158